NO20053761L - Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus. - Google Patents
Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus.Info
- Publication number
- NO20053761L NO20053761L NO20053761A NO20053761A NO20053761L NO 20053761 L NO20053761 L NO 20053761L NO 20053761 A NO20053761 A NO 20053761A NO 20053761 A NO20053761 A NO 20053761A NO 20053761 L NO20053761 L NO 20053761L
- Authority
- NO
- Norway
- Prior art keywords
- lupus erythematosus
- systemic lupus
- composition
- treatment
- peptide
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43995003P | 2003-01-14 | 2003-01-14 | |
| PCT/US2004/000955 WO2004064788A2 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053761D0 NO20053761D0 (no) | 2005-08-08 |
| NO20053761L true NO20053761L (no) | 2005-10-12 |
Family
ID=32771763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053761A NO20053761L (no) | 2003-01-14 | 2005-08-08 | Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7294687B2 (zh) |
| EP (1) | EP1587525A4 (zh) |
| JP (1) | JP2006516034A (zh) |
| KR (1) | KR20050100616A (zh) |
| CN (1) | CN1761477A (zh) |
| AU (1) | AU2004206844A1 (zh) |
| BR (1) | BRPI0406737A (zh) |
| CA (1) | CA2513331A1 (zh) |
| CO (1) | CO5640149A2 (zh) |
| CR (1) | CR7936A (zh) |
| EA (1) | EA008438B1 (zh) |
| EC (1) | ECSP055960A (zh) |
| MX (1) | MXPA05007552A (zh) |
| NO (1) | NO20053761L (zh) |
| NZ (1) | NZ541659A (zh) |
| UA (1) | UA83816C2 (zh) |
| WO (1) | WO2004064788A2 (zh) |
| ZA (1) | ZA200506205B (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141647A0 (en) | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| EA008438B1 (ru) * | 2003-01-14 | 2007-06-29 | Тева Фармасьютикал Индастриз, Лтд. | Парентеральные композиции пептида для лечения системной красной волчанки |
| EA009123B1 (ru) * | 2003-01-14 | 2007-10-26 | Тева Фармасьютикал Индастриз, Лтд. | Парентеральные композиции пептидов для лечения системной красной волчанки |
| DE102004043750A1 (de) * | 2004-09-10 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| WO2008073448A2 (en) * | 2006-12-12 | 2008-06-19 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations and methods for making the same |
| JP2010516626A (ja) * | 2007-01-16 | 2010-05-20 | バイパー サイエンシズ，インコーポレイティド | ガン治療剤 |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| AU2009279090A1 (en) | 2008-08-06 | 2010-02-11 | Novo Nordisk Health Care Ag | Conjugated proteins with prolonged in vivo efficacy |
| HUE058834T2 (hu) | 2012-02-15 | 2022-09-28 | Cydex Pharmaceuticals Inc | Elõállítási eljárás ciklodextrin-származékokhoz |
| WO2014066274A1 (en) | 2012-10-22 | 2014-05-01 | Cydex Pharmaceuticals, Inc. | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| FI3183295T3 (fi) | 2014-08-22 | 2023-09-25 | Cydex Pharmaceuticals Inc | Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi |
| AU2018205885A1 (en) | 2017-01-05 | 2019-06-27 | Yeda Research And Development Co. Ltd. | Peptides for treating Sjogren's syndrome |
| CN110960442B (zh) * | 2019-12-17 | 2023-03-31 | 珠海冀百康生物科技有限公司 | 一种多肽包封物的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60184098A (ja) * | 1984-03-02 | 1985-09-19 | Suntory Ltd | 新規なペプチド及びこれを有効成分とする利尿剤 |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| US6613536B1 (en) | 1995-03-28 | 2003-09-02 | Yeda Research And Development Co. Ltd. | Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| IL113159A0 (en) * | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| IL120503A0 (en) * | 1997-03-20 | 1997-07-13 | Hadasit Med Res Service | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
| US20020054872A1 (en) * | 1997-03-20 | 2002-05-09 | Yaakov Naparstek | Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
| US6054470A (en) | 1997-12-18 | 2000-04-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Src family SH2 domain inhibitors |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US7114005B2 (en) | 2002-02-05 | 2006-09-26 | Cisco Technology, Inc. | Address hopping of packet-based communications |
| EA009123B1 (ru) * | 2003-01-14 | 2007-10-26 | Тева Фармасьютикал Индастриз, Лтд. | Парентеральные композиции пептидов для лечения системной красной волчанки |
| EA008438B1 (ru) * | 2003-01-14 | 2007-06-29 | Тева Фармасьютикал Индастриз, Лтд. | Парентеральные композиции пептида для лечения системной красной волчанки |
-
2004
- 2004-01-14 EA EA200501129A patent/EA008438B1/ru not_active IP Right Cessation
- 2004-01-14 CN CNA2004800069919A patent/CN1761477A/zh active Pending
- 2004-01-14 AU AU2004206844A patent/AU2004206844A1/en not_active Abandoned
- 2004-01-14 EP EP04702214A patent/EP1587525A4/en not_active Withdrawn
- 2004-01-14 KR KR1020057013097A patent/KR20050100616A/ko not_active Application Discontinuation
- 2004-01-14 CA CA002513331A patent/CA2513331A1/en not_active Abandoned
- 2004-01-14 JP JP2006500958A patent/JP2006516034A/ja not_active Withdrawn
- 2004-01-14 NZ NZ541659A patent/NZ541659A/en unknown
- 2004-01-14 BR BR0406737-1A patent/BRPI0406737A/pt not_active IP Right Cessation
- 2004-01-14 UA UAA200507998A patent/UA83816C2/ru unknown
- 2004-01-14 MX MXPA05007552A patent/MXPA05007552A/es active IP Right Grant
- 2004-01-14 WO PCT/US2004/000955 patent/WO2004064788A2/en not_active Application Discontinuation
- 2004-01-14 US US10/758,572 patent/US7294687B2/en not_active Expired - Lifetime
-
2005
- 2005-08-03 ZA ZA200506205A patent/ZA200506205B/en unknown
- 2005-08-08 NO NO20053761A patent/NO20053761L/no not_active Application Discontinuation
- 2005-08-09 CR CR7936A patent/CR7936A/es unknown
- 2005-08-10 CO CO05079319A patent/CO5640149A2/es not_active Application Discontinuation
- 2005-08-11 EC EC2005005960A patent/ECSP055960A/es unknown
-
2007
- 2007-11-12 US US11/985,068 patent/US20080287366A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0406737A (pt) | 2005-12-20 |
| EA200501129A1 (ru) | 2006-02-24 |
| EA008438B1 (ru) | 2007-06-29 |
| WO2004064788A3 (en) | 2005-03-24 |
| CN1761477A (zh) | 2006-04-19 |
| US7294687B2 (en) | 2007-11-13 |
| MXPA05007552A (es) | 2006-05-19 |
| JP2006516034A (ja) | 2006-06-15 |
| AU2004206844A1 (en) | 2004-08-05 |
| EP1587525A4 (en) | 2008-09-10 |
| CR7936A (es) | 2006-05-31 |
| CA2513331A1 (en) | 2004-08-05 |
| US20040180059A1 (en) | 2004-09-16 |
| CO5640149A2 (es) | 2006-05-31 |
| ZA200506205B (en) | 2006-12-27 |
| EP1587525A2 (en) | 2005-10-26 |
| ECSP055960A (es) | 2006-04-19 |
| UA83816C2 (ru) | 2008-08-26 |
| NZ541659A (en) | 2007-05-31 |
| KR20050100616A (ko) | 2005-10-19 |
| NO20053761D0 (no) | 2005-08-08 |
| US20080287366A1 (en) | 2008-11-20 |
| WO2004064788A2 (en) | 2004-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053761L (no) | Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus. | |
| CR7938A (es) | Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico | |
| ES2387848T3 (es) | Composiciones para el tratamiento de trastornos gastrointestinales | |
| ES2523858T3 (es) | Fragmentos de VIP y composiciones de los mismos | |
| CA2729938A1 (en) | New insulin analogues of prolonged activity | |
| US20220118105A1 (en) | CD38 Antibody Drug Conjugate | |
| CN113194983A (zh) | 用于治疗病毒感染的组合物及方法 | |
| RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| NZ597554A (en) | Selective glucagon-like-peptide-2 (glp-2) analogues | |
| US20070099841A1 (en) | Prodrugs of T3 and T4 with enhanced bioavailability | |
| CA2649360A1 (en) | Mono and di-substituted oxycodone compounds and compositions | |
| JP2016084357A (ja) | エンドモルフィンのμオピオイド受容体アゴニスト類似体 | |
| SK11242002A3 (sk) | Zlúčenina, spôsob prípravy zlúčeniny, farmaceutický prostriedok a spôsob liečenia rakoviny | |
| AU2001277908A1 (en) | Medicinal uses of mu-opioid receptor agonists | |
| JP6656661B2 (ja) | プレキシンの結合調節剤 | |
| CA2374270A1 (en) | Labeled neurotensin derivatives | |
| JPWO2016063969A1 (ja) | ヘマグルチニン結合ペプチド | |
| US7087575B2 (en) | Treating the effect of nicotine | |
| KR19990044554A (ko) | 펩티드 유도체 | |
| WO1999033864A1 (fr) | Derives peptidiques | |
| US5071836A (en) | Competitive gonadoliberin antagonists | |
| KR19990044553A (ko) | 펩티드 유도체 | |
| WO2007145208A1 (ja) | ペプチド誘導体 | |
| JP7437578B2 (ja) | 新規オピオイドペプチド、その糖鎖付加体及びそれらを含む医薬組成物 | |
| JPH06509571A (ja) | タキキニン拮抗薬としての環状ヘキサペプチドの製法およびその薬学的化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |